摘要
目的：观察足叶乙甙（VP16）联合CAG方案[粒细胞集落刺激因子（G-CSF）＋Ara-C＋阿柔比星（ACLA）]治疗难治性急性髓细胞白血病（AML）的疗效和安全性。方法：对患者进行VP16联合CAG方案诱导缓解治疗。治疗过程中,监测患者临床表现、血常规、血生化和骨髓细胞学检查指标。结果：15例患者接受本方案治疗,其中男性7例,女性8例,中位年龄32岁（18-52岁）。完全缓解（CR）9例,部分缓解（PR）2例,未缓解（NR）4例。CR率60%,总反应率（CR＋PR）73.3%。最常见的毒副反应为骨髓抑制,其次为感染,以肺部感染最常见（发生率为33.3%）。结论：VP16联合CAG方案诱导治疗难治性AML是有效且安全的。
Objective：To evaluate the efficacy and safety of treatment of refractory AML with VP16 combining CAG regimen. Methods：Vpl6 combining CAG regimen was administered to patients with refractory AML. Clinical manifestations, blood count, blood biochemical parameters and bone marrow smears were measured during the courses. Results： 15 patients, including 7 male and 8 female, were enrolled. Median age was 32 （ 18 -52） years old. 9 patients reached CR, 2PR and 4NR. CR rate was 60% and total response rate （ CR ＋ PR） was 73.3%. The most commonly observed side effect of the regimen was bone marrow proliferation inhibition, and followed by infections, usually respiratory tract infections. Conclusions： VP16 combining CAG regimen as remission induction chemotherapy in patients with refractory AML was effective and safety.
出处
《中国民康医学》
2008年第9期866-867,869,共3页
Medical Journal of Chinese People’s Health
关键词
足叶乙甙
阿糖胞苷
粒细胞集落刺激因子
阿柔比星
急性髓系白血病
Etopside
Cytosine arabinoside
Granulocyte - colony - stimulating - factor： Aclamycin
Acute myloid leukemia
